Health Canada (Re), 2022 OIC 52

The complainant alleged that Health Canada improperly withheld information under paragraphs 20(1)(b) and 20(1)(c) of the Access to Information Act. The request sought two versions of a non-clinical overview of the Novavax SARS CoV-2 rS vaccine. Health Canada applied paragraph 20(1)(b) to withhold the information, arguing it was confidential third-party scientific or technical information. The OIC found that the information met all criteria for exemption under paragraph 20(1)(b), including being scientific/technical, confidential, supplied by a third party, and consistently treated as confidential. The OIC also concluded that the circumstances requiring Health Canada to exercise discretion under subsections 20(5) or 20(6) did not exist, as Novavax did not consent to disclosure and the public interest in disclosure did not clearly outweigh potential harm to Novavax at the time of the decision. Consequently, the complaint was deemed not well founded.